Share Twitter LinkedIn Facebook Email Elisha Hughes, Ph.D., Director of Research Biostatistics at Myriad Genetics, Inc. speaks about the SABCS Abstract – P2-11-21 Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model.
FDA Approves Datopotamab Deruxtecan / Datroway from Eli Lilly in Treatment for Unresectable or Metastatic HR-Positive, HER2-Negative Breast Cancer Breast 2 Mins Read
Can Imlunestrant Change the Future of Breast Cancer Treatment? Insights from SABCS with Virginia Kaklamani, MD Breast 3 Mins Read